Presentation Overview:
This webinar focuses on critical design and process development steps to ensure the optimization and scale-up of ADCs and bioconjugates. By starting smart, we can finish fast and maximize chances of success. It covers the following areas:
Designing Next Generation Bioconjugates
- Selecting Target and Targeting Moiety
- From Linker-Payload to Conjugate
Process Development and Manufacturing Considerations for Next-Gen Conjugates
- Incorporating Next-Generation Conjugation Technologies into ADC Manufacturing – Engineered Cysteines ADCs
- Manufacturing Strategies for Novel Payloads Conjugates – Radioimmunoconjugates and Oligonucleotides Conjugates
Learning Objectives:
- Considerations for designing next-generation bioconjugates.
- Process development and manufacturing considerations for next-generation conjugates.
About Our Speakers
- Principal scientist at Abzena focusing on Early to Late Phase bioconjugation development and manufacturing of ADCs.
- R&D lead for novel-format bioconjugation strategies and development.
- Led projects for integrated programs supporting batch execution, tech transfer and providing manufacturing support for ADCs.
- Background in chemical biology, bioconjugation and biorthogonal chemistry
- Doctoral work in the field of biorthogonal chemistry, working with novel intramolecular lewis acid catalyzed click reactions.
- Developed novel strategies to combine enzymatic and click reactions in single vessel immunoprecipitation of proteins.
- Ph. D. in Chemistry from State University of New York at Binghamton.
Biconjugation expert with 3 years of experience in ADC process development and manufacturing.
Manager at Abzena focusing on Process Development and Manufacture of Bioconjugate Therapies.
- Supporting manufacturing and process development for ADCs and novel-format bioconjugate modalities.
- Development and Manufacture lead for over 8 ADC, Protein-Oligonucleotide conjugates, and Radio-immunoconjugates currently in clinical trials.
Background in viral vector mediated gene-therapy process development and manufacturing.
- Platform development for upstream and downstream processes for AAV and Lenti viral vectors at Wuxi Advanced Therapies
- Bachelors in Pharmacology and Toxicology from University of the Sciences
Access this on-demand webinar:
